Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2012, Vol. 10 ›› Issue (2): 176-185.doi: 10.3736/jcim20120208

• Original Clinical Research • Previous Articles     Next Articles

A prospective cohort study on the influence of high doses of herbs for clearing heat and resolving stasis on survival rates in patients with hepatitis B-related acute-on-chronic liver failure

Hu Xiao-Yu1,Zhang Yang2,Chen Guo1,Zhong Sen1,Fan Xin-Jian2   

  1. 1. Department of Infectious Diseases, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China
    2. Clinic College of Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China
  • Received:2011-10-20 Accepted:2011-12-17 Online:2012-02-20 Published:2018-10-09

BACKGROUND: Hepatitis B-related acute-on-chronic liver failure (ACLF) is a severe clinical syndrome characterized by jaundice, coagulopathy, ascites and hepatic encephalopathy and with a high mortality rate of 65% to 93%. It involves significant ethical issues when a randomized, double-blinded, placebo-controlled clinical study is conducted to such a serious disease. Therefore, a prospective cohort study design was utilized to explore a new treatment modality of applying integrated traditional Chinese and Western medicine.
OBJECTIVE: To evaluate the efficacy, safety and recent survival rates of high-dose herbs with the function of clearing heat and resolving stasis, named Qingre Huayu, in patients with hepatitis B-related ACLF with heat toxin stagnation syndrome.
DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: A matched, prospective cohort study was conducted. Participants who met the inclusion criteria were recruited from the Department of Infectious Diseases, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine. Patients were assigned to either an integrated medicine group or a Western medicine group according to their own preference and received either a regime of classic Western medical treatment (control group) or a regime of classic Western medical treatment plus Qingre Huayu herbs (treatment group). The regimes were conducted for 12 weeks.
MAIN OUTCOME MEASURES: Survival rates of non-liver transplantation patients were evaluated after 12-week treatment. The levels of total bilirubin (TBiL), albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and prothrombin activity (PTA) were detected at baseline and weeks 4, 8 and 12. Scores of traditional Chinese medicine (TCM) syndrome and complications were evaluated at baseline and study completion. Adverse events were recorded.
RESULTS: All patients were followed up to the deadline for this study. There were 21 cases (31.8%) who died in the treatment group (n=66) and 19 cases (59.4%) in the control group (n=32). Significant difference (χ 2=6.775, P<0.01) was found in comparing the survival and death rates between the two groups by χ 2 test. At 12 weeks, mean survival time of the two groups was 69.9 and 47.2 d respectively; cumulative survival rate of patients in the treatment group was higher than that of patients in the control group (P<0.01). Levels of TBiL, ALT, AST, ALB and PTA at weeks 4, 8 and 12 in the treatment group were superior to those in the control group with statistical significance (P<0.01 or P<0.05). In comparison of the TCM syndrome scores at week 12, the average score of the TCM syndrome of the treatment group (n=45) was 7.52±2.41, lower than 18.34±4.36 of the control group (n=13), and the difference was significant (t=8.784, P<0.01). Complication incidences after 12 weeks of treatment were statistically different between the treatment group (n=45) and the control group (n=13) by χ 2 test (P<0.05 or P<0.01). Incidence rates of ascites, infection and hepatic encephalopathy accounted for 22.22% (10/45) and 69.23% (9/13), 8.89% (4/45) and 53.85% (7/13), and 11.11% (5/45) and 46.15% (6/13) in the two groups respectively. The incidence rates of adverse events in the treatment group and the control group were 0.00% and 12.50% respectively and the difference was statistically significant (χ 2=5.705, P<0.05). No drug-related adverse events were found in blood, urine and stool routine tests, renal function test and electrocardiography.
CONCLUSION: High doses of Qingre Huayu herbs can significantly improve liver function and coagulation function, reduce complications, and reduce mortality in patients with hepatitis B-related ACLF.

Key words: drugs, Chinese herbal, liver failure, clearing heat and resolving stasis, survival rate, syndrome, complications, cohort studies, prospective studies

Figure 1

Flow chart of this clinical research"

Table 1

Baseline data comparison between the two groups"

Item Treatment group (n=66) Control group (n=32) P value
Age (x±s, years) 45.7±14.7 44.9±13.9 0.798
Male (n, %) 47 (71.2) 22 (68.8) 0.802
HBeAg-positive (n, %) 30 (45.5) 16 (50.0) 0.672
HBV DNA (Median (Q1, Q3), log10 copies/mL) 5.8 (4.3, 7.2) 5.8 (4.5, 7.0) 0.421
Abnormal rate of ALT (%) 86.4 81.3 0.719
ALT level (x±s, U/L) 231.45±75.38 229.36±76.73 0.898
CPT score (Median (Q1, Q3)) 9 (7, 11) 9 (8, 11) 0.515
MELD score (Median (Q1, Q3)) 26 (18, 37) 24 (16, 35) 0.347

Figure 2

Survival curve of non-liver transplantation patients in two groups after 12-week treatment"

Table 2

Comparison of blood TBiL level between the two groups (x±s, μmol/L)"

Group Baseline 4 weeks 8 weeks 12 weeks
n TBiL n TBiL n TBiL n TBiL
Treatment 66 487.43±127.62 57 295.21±87.64 52 169.51±53.41 45 86.31±30.44
Control 32 476.62±139.23 17 464.27±134.63 14 452.23±131.38 13 432.54±125.37
T value 0.382 4.878 7.878 9.874
P value 0.704 0.000 0.000 0.000

Table 3

Comparison of blood ALT level between the two groups (x±s, U/L)"

Group Baseline 4 weeks 8 weeks 12 weeks
Treatment 66 231.45±75.38 57 120.33±39.66 52 66.58±21.52 45 43.71±12.79
Control 32 229.36±76.73 17 152.65±43.81 14 92.55±29.16 13 85.36±28.44
t value 0.128 2.879 3.706 7.613
P value 0.898 0.005 0.000 0.000

Table 4

Comparison of blood AST level between the two groups (x±s, U/L)"

Group Baseline 4 weeks 8 weeks 12 weeks
Treatment 66 217.45±69.51 57 98.37±31.56 52 57.61±18.73 45 39.43±12.68
Control 32 208.36±70.45 17 135.42±44.71 14 86.96±26.57 13 82.39±28.71
t value 0.604 3.188 3.882 5.249
P value 0.547 0.005 0.001 0.000

Table 5

Comparison of blood albumin level between the two groups (x±s, g/L)"

Group Baseline 4 weeks 8 weeks 12 weeks
n Albumin n Albumin n Albumin n Albumin
Treatment 66 25.56±6.79 57 27.64±7.83 52 32.61±9.34 45 35.46±10.51
Control 32 24.37±7.12 17 25.37±7.24 14 26.39±8.73 13 28.25±8.76
t value 0.801 2.006 2.241 2.254
P value 0.425 0.049 0.029 0.028

Table 6

Comparison of PTA level between the two groups(x±s, %)"

Group Baseline 4 weeks 8 weeks 12 weeks
Treatment 66 32.54±10.23 57 40.69±10.78 52 49.18±12.51 45 54.27±15.66
Control 32 31.67±9.78 17 33.52±11.46 14 34.25±12.84 13 38.37±13.09
t value 0.400 2.373 3.942 3.334
P value 0.690 0.020 0.000 0.002
[1] Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF . Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009; 3(1):269-282.
doi: 10.1007/s12072-008-9106-x
[2] Zhao ZG, Han T, Gao YT, Gao YY, Zhang Y, Wu ZP . Causes and clinical outcomes of acute-on-chronic liver failure in patients with hepatitis B virus infection: an analysis of 289 cases. Shi Jie Hua Ren Xiao Hua Za Zhi. 2009; 17(31): 3269-3272. Chinese with abstract in English.
赵振刚, 韩涛, 髙英堂, 髙艳颖, 张晔, 吴珍萍 . 乙型肝炎患者并发慢加急性肝衰竭诱因及转归分析289例. 世界华人消化杂志. 2009; 17(31):3269-3272.
[3] Tsang SW, Chan HL, Leung NW, Chau TN, Lai ST, Chan FK, Sung JJ . Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment Pharmacol Ther. 2001; 15(11):1737-1744.
doi: 10.1046/j.1365-2036.2001.01107.x
[4] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic and treatment guidelines for liver failure. Zhonghua Gan Zang Bing Za Zhi. 2006; 14(9): 643-646. Chinese.
中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊疗指南.中华肝脏病杂志. 2006; 14(9):643-646.
[5] Professional Committee of Hepatology, China Association of Traditional Chinese Medicine. Criteria of differentiation of symptoms and sings of traditional Chinese medicine for viral hepatitis ( trial implementation) . Zhong Yi Za Zhi. 1992; ( 5) : 39-40. Chinese.
中国中医药学会内科肝病专业委员会. 病毒性肝炎中医辨证标准(试行).中医杂志. 1992; ( 5):39-40.
[6] Zheng XY. Guidelines for clinical research on Chinese new herbal medicines (trial implementation). Beijing: China Medical Science Press. 2002 : 147-148. Chinese.
郑筱萸 . 中药新药临床研究指导原则(试行).北京: 中国医药科技出版社. 2002: 147-148.
[7] Zhao ZT. Research methods of epidemiology and their application. Beijing: Science Press. 2005: 120. Chinese.
赵仲堂 . 流行病学研究方法与应用.北京: 科学出版社. 2005: 120.
[8] Chinese Society of Hepatology and Chinese Society of Infectious Diseases and Parasitic Diseases of Chinese Medical Association. Prevention and treatment program of viral hepatitis. Zhonghua Gan Zang Bing Za Zhi. 2000; 8(6): 324-329. Chinese.
中华医学会传染病与寄生虫病学分会、肝病学分会. 病毒性肝炎防治方案.中华肝脏病杂志. 2000; 8(6):324-329.
[9] Zheng HW, Jia JD . Current status in the diagnosis and treatment of liver failure. Chuan Ran Bing Xin Xi. 2007; 20(3): 139-142. Chinese.
郑欢伟, 贾继东 . 肝衰竭的诊断和治疗现状.传染病信息. 2007; 20(3):139-142.
[10] Chen LM, Ye WH, Wang LJ, Xu CJ, Geng H, Li YY, Chen JM . Clinical analysis of acute-on-chronic liver failure and chronic liver failure. Chuan Ran Bing Xin Xi. 2007; 20(4): 234-235. Chinese with abstract in English.
doi: 10.3969/j.issn.1007-8134.2007.04.014
陈黎明, 叶文华, 王陆军, 徐长江, 耿华, 李元元, 陈菊梅 . 慢加急性肝衰竭与慢性肝衰竭的临床分析.传染病信息. 2007; 20(4):234-235.
doi: 10.3969/j.issn.1007-8134.2007.04.014
[11] Yang X, Zhao HX, Xu QT . Clinical analysis of 101 cases with acute-on-chronic liver failure. Lin Chuang Gan Dan Bing Za Zhi. 2009; 25(3): 372-373. Chinese with abstract in English.
杨萱, 赵红霞, 许青田 . 慢加急性肝衰竭101例临床分析.临床肝胆病杂志. 2009; 25(3):372-373.
[12] Liu JP . Design, implementation and methodological issues in cohort study. J Chin Integr Med. 2008; 6(4): 331-336. Chinese with abstract in English.
刘建平 . 队列研究的设计、实施及方法学问题.中西医结合学报. 2008; 6(4):331-336.
[13] Hu LP, Bao XL, Wang Q . The control principle in scientific research. J Chin Integr Med. 2011 ; 9(8): 834-837. English with abstract in Chinese.
胡良平, 鲍晓蕾, 王琪 . 科研设计应遵守对照原则.中西医结合学报. 2011; 9(8):834-837.
[1] Sherman Gu, Arthur Yin Fan. Controversial conclusions from two randomized controlled trials for acupuncture's effects on polycystic ovary syndrome or in vitro fertilization support. Journal of Integrative Medicine, 2020, 18(2): 89-91.
[2] Xue-qing Yu, Shu-guang Yang, Yang Xie, Jian-sheng Li. Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of exploratory trial. Journal of Integrative Medicine, 2020, 18(2): 163-168.
[3] Rebecca Kulbida, Alexander Mathes, Johannes Loeser. Beneficial effects of hirudotherapy in a chronic case of complex regional pain syndrome. Journal of Integrative Medicine, 2019, 17(5): 383-386.
[4] Sonia Chew Wen Phang, Uma Devi Palanisamy, Khalid Abdul Kadir. Effects of geraniin (rambutan rind extract) on blood pressure and metabolic parameters in rats fed high-fat diet. Journal of Integrative Medicine, 2019, 17(2): 100-106.
[5] Mehranghiz Ebrahimi-Mameghani, Mohammad Asghari-Jafarabadi, Khatereh Rezazadeh. TCF7L2-rs7903146 polymorphism modulates the effect of artichoke leaf extract supplementation on insulin resistance in metabolic syndrome: A randomized, double-blind, placebo-controlled trial. Journal of Integrative Medicine, 2018, 16(5): 329-334.
[6] Chen Fu, Nevin Lianwen Zhang, Bao-xin Chen, Zhou Rong Chen, Xiang Lan Jin, Rong-juan Guo, Zhi-gang Chen, Yun-ling Zhang. Identification and classification of traditional Chinese medicine syndrome types among senior patients with vascular mild cognitive impairment using latent tree analysis. Journal of Integrative Medicine, 2017, 15(3): 186-200.
[7] Qian-wen Ma, Yong Tan. Effectiveness of co-treatment with traditional Chinese medicine and letrozole for polycystic ovary syndrome: A meta-analysis. Journal of Integrative Medicine, 2017, 15(2): 95-101.
[8] Jin Yu, Chao-qin Yu, Qi Cao, Li Wang, Wen-jun Wang, Li-rong Zhou, Jing Li, Qiao-hong Qian. Consensus on the integrated traditional Chinese and Western medicine criteria of diagnostic classification in polycystic ovary syndrome (draft). Journal of Integrative Medicine, 2017, 15(2): 102-109.
[9] Nevin Lianwen Zhang, Chen Fu, Teng Fei Liu, Bao-xin Chen, Kin Man Poon, Pei Xian Chen, Yunling Zhang. A data-driven method for syndrome type identification and classification in traditional Chinese medicine. Journal of Integrative Medicine, 2017, 15(2): 110-123.
[10] Yu-fangLin, Zhi-danLiu, WenMa, Wei-dongShen. Hazards of insomnia and the effects of acupuncture treatment on insomnia. Journal of Integrative Medicine, 2016, 14(3): 174-186.
[11] Nathalia Gomes Ribeiro de Moura, Ivan Cordovil, Arthurde Sá Ferreira. Traditional Chinese medicine wrist pulse-taking is associated with pulse waveform analysis and hemodynamics in hypertension. Journal of Integrative Medicine, 2016, 14(2): 100-113.
[12] Qing Ji, Yun-quan Luo, Wen-hai Wang, Xuan Liu, Qi Li, Shi-bing Su. Research advances in traditional Chinese medicine syndromes in cancer patients. Journal of Integrative Medicine, 2016, 14(1): 12-21.
[13] Reshma M.Ansari. Potential use of durian fruit (Durio zibenthinus Linn) as an adjunct to treat infertility in polycystic ovarian syndrome. Journal of Integrative Medicine, 2016, 14(1): 22-28.
[14] May To, Caroline Alexander. The effects of Park sham needles: A pilot study. Journal of Integrative Medicine, 2015, 13(1): 20-24.
[15] Yong-hong Lian, Mei-xia Fang, Li-guo Chen. Constructing protein-protein interaction network of hypertension with blood stasis syndrome via digital gene expression sequencing and database mining. Journal of Integrative Medicine, 2014, 12(6): 476-482.
Full text



[1] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. An explanation on "guiding principles of clinical research on mild cognitive impairment (protocol)". Journal of Chinese Integrative Medicine, 2008, 6(1): 15-21
[2] Jin-rong Fu. Establishment of multivariate diagnosis and treatment system of modern gynecology of traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 22-24
[3] SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[4] A-gao Zhou, Yong Zhang, Gang Kui, De-Yun Kong, Hai-liang Ge, Qiu-hua Ren, Jia-rong Dong, Sheng Hong, Xu-ming Mao, Yin Wang, Hui-zheng Zhang, Shu-jun Wang. Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 77-82
[5] Xi Lin, Jian-ping Liu. Tai chi for treating rheumatoid arthritis. Journal of Chinese Integrative Medicine, 2008, 6(1): 82
[6] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[7] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. Guiding principles of clinical research on mild cognitive impairment (protocol). Journal of Chinese Integrative Medicine, 2008, 6(1): 9-14
[8] Daniel Weber, Janelle M Wheat, Geoffrey M Currie. Inflammation and cancer: Tumor initiation, progression and metastasis,and Chinese botanical medicines. Journal of Chinese Integrative Medicine, 2010, 8(11): 1006-1013
[9] Bo Wang , Wei Yan , Li-hui Hou, Xiao-ke Wu. Disorder of Tiangui (kidney essence) and reproductive dysfunction in patients with polycystic ovary syndrome. Journal of Chinese Integrative Medicine, 2010, 8(11): 1018-1022
[10] Ya-bing Zhou, Jian-er Yu, Jie Wu, Li Bai, Li-li Huo, Xin-guang Zhang, Li-qing Li . Effects of Chinese herbal medicine Bushen Gubiao Recipe on toll-like receptor 4 and CD4 +CD25 +foxp3 +regulatory T cells in mice with recurrent respiratory tract infections. Journal of Chinese Integrative Medicine, 2010, 8(11): 1053-1059